HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearchCompany Lookup
The Week

'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff

Staring down a $6 billion patent cliff for its prostate cancer drug Xtandi, Astellas aims to counter the inevitable revenue decline with a 200 billion yen ($1.3 billion) cost-savings program anchored in its new five-year strategic plan. But to CEO Naoki Okamura, "it's not simply saving the cost or r

By FierceBiotech · Jun 14, 2026 · via FierceBiotech
'Not simply saving cost': Inside Astellas CEO's 5-year strategy to counter Xtandi's patent cliff

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.

Tags
theweekformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
CG Life embraces next-gen era in merger with AI-native agency The Considered+AI
The Considered+AI is an AI-native agency that's been rooted in generative AI tools since its start in 2021.…
Jul 29, 2026
The WeekFierceBiotech ↗
Eli Lilly tops new biopharma ranking on launch success, development speed
Flush with GLP-1 cash and pipeline success, Eli Lilly rose from 16th to first over five years in Norstella's i…
Jul 29, 2026
Freenome gets FDA signoff, Abbott takes the U.S. commercialization role
The WeekBriefing
Freenome gets FDA signoff, Abbott takes the U.S. commercialization role
Freenome’s blood-based colorectal cancer test won FDA approval, and Abbott will exclusively market it in the U…
Jul 29, 2026